AGMB Overview

Agomab Therapeutics NV is a Belgium-based biotech company. The Company is engaged in the development of antibodies for damaged tissues. It develops novel treatments that aim to preserve and restore organ function in fibrotic diseases. It also develops growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. The Company targets growth factors and modulates related molecular pathways through monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate tissue and restore organ functionality. It works with academic institutions and industrial partners to develop treatment options for patients.

Wall Street analysts forecast AGMB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGMB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Agomab Therapeutics NV revenue for the last quarter amounts to NaN USD, decreased % YoY.

Agomab Therapeutics NV. EPS for the last quarter amounts to USD, decreased % YoY.

Agomab Therapeutics NV (AGMB) has 0 emplpoyees as of February 08 2026.

Today AGMB has the market capitalization of 713.99M USD.